CG Oncology, Inc. Common stock
NASDAQ:CGONBiotechnology
+$1.35 today
- Market cap
- $7.15B
- Beta
- 0.31
- P/E (TTM)
- -28.0
- EPS (TTM)
- -$2.21
Volume 1.79M
Average 1.08M
CGON Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
CG Oncology, Inc. Common stockNASDAQ: CGON
Research & Development · Q3 FY2026 · quarter ended Sep 2026
Research & development grows, but more slowly than its trailing trend
Q3 FY2026 research & development of $39.22M rose 40.7% year over year, behind the +47.7% change in trailing-twelve-month research & development. Sequentially, it fell 28.2% from the prior quarter. Over 3 fiscal years it compounded at +59.0% a year.
Context
- Research & development amounted to 2887.2% of revenue in FY2025, down 4321.1 pp from a year earlier.
- Research & development increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +40.7% toward the trailing-twelve-month pace of +47.7%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 116.64M USD
- Year-over-year change
- +42.1%
- 4-year CAGR
- +58.9%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 116.64M | +42.1% |
| FY2024 | 2024-12-31 | 82.1M | +79.5% |
| FY2023 | 2023-12-31 | 45.75M | +57.6% |
| FY2022 | 2022-12-31 | 29.03M | +58.5% |
| FY2021 | 2021-12-31 | 18.32M | — |
Research & Development vs competitors
How CGON compares with its peers on the latest reported figures
- CGON's LTM Sep 2026 research & development of $167.57M is the 2nd highest of the 3 companies compared; the peer median is $157.53M.
- Its year-over-year change of +47.7% is the highest of 3, against a peer median of +17.6%.
- Research & development amounts to 2717.6% of revenue for CGON, versus a peer median of 91.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $252.23M | +33.2% | -5.7% | 138.2% | |
| LTM Sep 2026 | $167.57M | +47.7% | +59.0% | 2717.6% | |
| LTM Mar 2026 | $62.83M | +2.1% | +8.2% | 44.7% | |
| Peer median (excluding CGON) | $157.53M | +17.6% | +1.3% | 91.4% | |
Competitors are the stored peer set for CGON. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 10.36M | 191K | 204K | 1.14M | 4.04M |
| Cost of Revenue | 10K | 15K | 45.75M | 82.1M | 4.65M |
| Gross Profit | 10.35M | 176K | (45.55M) | (80.96M) | (607K) |
| Gross Margin | 99.9% | 92.1% | -22327.5% | -7108.3% | -15.0% |
| Research & Development | 18.32M | 29.03M | 45.75M | 82.1M | 116.64M |
| Selling, General & Admin | 4.64M | 6.39M | 9.9M | 33.7M | 73.53M |
| Operating Expenses | 22.95M | 35.42M | 9.9M | 33.7M | 190.17M |
| Depreciation & Amortization | 10K | 15K | 17K | 32K | 1.45M |
| EBITDA | (12.38M) | (35.43M) | (48.59M) | (88.01M) | (159.55M) |
| EBITDA Margin | -119.5% | -18548.2% | -23818.6% | -7726.7% | -3949.3% |
| Operating Income | (12.61M) | (35.25M) | (55.45M) | (114.67M) | (190.77M) |
| Operating Margin | -121.7% | -18453.4% | -27180.9% | -10067.3% | -4722.1% |
| Interest Income | 0 | 0 | 6.9M | 26.62M | 29.93M |
| Interest Expense | 451K | 1K | 0 | 0 | 0 |
| Other Income / Expenses | (233K) | (197K) | 6.84M | 26.63M | 29.78M |
| Income Before Tax | (12.84M) | (35.44M) | (48.61M) | (88.04M) | (161M) |
| Pre-Tax Margin | -124.0% | -18556.5% | -23827.0% | -7729.5% | -3985.0% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (12.84M) | (35.44M) | (48.61M) | (88.04M) | (161M) |
| Net Margin | -124.0% | -18556.5% | -23827.0% | -7729.5% | -3985.0% |
| EPS (Basic) | (0.28) | (0.66) | (1.02) | (1.41) | (2.08) |
| EPS (Diluted) | (0.28) | (0.66) | (1.02) | (1.41) | (2.08) |
| Weighted Avg Shares | 66.64M | 66.64M | 66.64M | 62.5M | 77.3M |
| Weighted Avg Shares (Diluted) | 66.64M | 66.64M | 66.64M | 62.5M | 77.3M |
CG Oncology, Inc. Common stock
NASDAQ:CGON
Intrinsic Alpha fair value
Locked
Current Price
$80.00
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.